← All trials
NCT06132789
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 27, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Jun 30, 2024
- First posted
- Nov 15, 2023
- Last posted
- Dec 11, 2023
- Enrollment
- 80
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ab&b Biotechnology Co., Ltd.Lead sponsor
- Government of ChinaCollaborator
- Government of ChinaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.